Detalles de la búsqueda
1.
Preclinical pharmacokinetics and metabolism of MAK683, a clinical stage selective oral embryonic ectoderm development (EED) inhibitor for cancer treatment.
Xenobiotica
; 52(1): 65-78, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34761729
2.
Increasing metabolic stability via the deuterium kinetic isotope effect: An example from a proline-amide-urea aminothiazole series of phosphatidylinositol-3 kinase alpha inhibitors.
Bioorg Med Chem Lett
; 26(19): 4729-4734, 2016 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27575470
3.
Orally bioavailable Syk inhibitors with activity in a rat PK/PD model.
Bioorg Med Chem Lett
; 25(20): 4642-7, 2015 Oct 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26320624
4.
Identification and optimisation of 4,5-dihydrobenzo[1,2-d:3,4-d]bisthiazole and 4,5-dihydrothiazolo[4,5-h]quinazoline series of selective phosphatidylinositol-3 kinase alpha inhibitors.
Bioorg Med Chem Lett
; 25(17): 3575-81, 2015 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26199119
5.
Syk inhibitors with high potency in presence of blood.
Bioorg Med Chem Lett
; 24(10): 2278-82, 2014 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24726806
6.
Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.
Bioorg Med Chem Lett
; 23(13): 3741-8, 2013 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23726034
7.
Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies.
J Med Chem
; 65(7): 5317-5333, 2022 04 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-35352560
8.
Exploring subtype selectivity and metabolic stability of a novel series of ligands for the benzodiazepine binding site of the GABAA receptor.
Bioorg Med Chem Lett
; 21(5): 1523-6, 2011 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21277199
9.
Evaluation of relative MS response factors of drug metabolites for semi-quantitative assessment of chemical liabilities in drug discovery.
J Mass Spectrom
; 52(4): 210-217, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28152561
10.
Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors.
ACS Med Chem Lett
; 8(9): 975-980, 2017 Sep 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-28947947
11.
Discovery of Imidazoquinolines as a Novel Class of Potent, Selective, and in Vivo Efficacious Cancer Osaka Thyroid (COT) Kinase Inhibitors.
J Med Chem
; 59(16): 7544-60, 2016 08 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-27502541
12.
Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors.
ACS Med Chem Lett
; 7(8): 762-7, 2016 Aug 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27563400
13.
Discovery and profiling of a selective and efficacious Syk inhibitor.
J Med Chem
; 58(4): 1950-63, 2015 Feb 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-25633741
14.
Micropreparative isolation and NMR structure elucidation of metabolites of the drug candidate 1-isopropyl-4-(4-isopropylphenyl)-6-(prop-2-yn-1-yloxy) quinazolin-2(1H)-one from rat bile and urine.
J Chromatogr B Analyt Technol Biomed Life Sci
; 989: 1-10, 2015 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25797717
15.
Benzimidazoles as Potent and Orally Active mGlu5 Receptor Antagonists with an Improved PK Profile.
ACS Med Chem Lett
; 2(1): 58-62, 2011 Jan 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-24900255
Resultados
1 -
15
de 15
1
Próxima >
>>